CareDx is a global transplant diagnostics company with product offerings along the pre- and post-transplant continuum. The Company focuses on discovery, development, and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant patients. CareDx's first commercialized post-transplant testing solution, the AlloMap heart transplant molecular test, or AlloMap, is a gene expression testing service that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate-to-severe acute cellular rejection.

The Company believes the use of AlloMap, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a heart transplant. In particular, AlloMap can improve patient care by helping healthcare providers avoid the use of unnecessary, invasive surveillance biopsies and determine the appropriate dosage levels of immunosuppressants. The Company is also pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure, its proprietary next-generation sequencing-based test to detect donor-derived cell-free DNA, or dd-cfDNA, after transplantation.

Company Growth (employees)
Type
Public
HQ
Brisbane, US
Founded
2000
Size (employees)
55 (est)
CareDx was founded in 2000 and is headquartered in Brisbane, US

CareDx Office Locations

CareDx has an office in Brisbane
Brisbane, US (HQ)
3260 Bayshore Blvd

CareDx Data and Metrics

CareDx Financial Metrics

CareDx's revenue was reported to be $11.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

11.6 m

Net income (Q1, 2017)

(5.6 m)

EBIT (Q1, 2017)

(8.5 m)

Market capitalization (15-Aug-2017)

38.5 m

Cash (31-Mar-2017)

12.2 m
CareDx's current market capitalization is $38.5 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

27.3 m28.1 m40.6 m

Revenue growth, %

3%44%

Sales and marketing expense

6.5 m8.3 m11.2 m

R&D expense

3.8 m9.3 m12.4 m

General and administrative expense

8.4 m12.2 m20.7 m

Operating expense total

26.1 m40.1 m78 m

EBIT

1.3 m(11.9 m)(37.3 m)

EBIT margin, %

5%(42%)(92%)

Interest expense

(2.1 m)(1.6 m)(1.9 m)

Pre tax profit

(719 k)(13.7 m)(41.4 m)

Income tax expense

1.5 m1.6 m

Net Income

781 k(13.7 m)(39.8 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

7.1 m7.2 m6.6 m10.7 m12.5 m11.6 m

Sales and marketing expense

2.5 m2.1 m1.7 m3.4 m3.5 m3.2 m

R&D expense

2.5 m2.7 m3.2 m3.1 m2.9 m3.3 m

General and administrative expense

2.3 m3.4 m5.7 m5.4 m5.2 m6.5 m

Operating expense total

7.4 m8.1 m10.6 m11.9 m11.6 m13 m

EBIT

(2.9 m)(3.2 m)(6.6 m)(7 m)(4.9 m)(8.5 m)

EBIT margin, %

(40%)(45%)(100%)(65%)(40%)(74%)

Interest expense

(256 k)(251 k)(266 k)(526 k)(568 k)(790 k)

Pre tax profit

(3.2 m)(3.5 m)(10.9 m)(4.2 m)(5.9 m)

Income tax expense

440 k449 k283 k

Net Income

(3.2 m)(3.5 m)(9.8 m)(10.5 m)(3.8 m)(5.6 m)
USDFY, 2014FY, 2015FY, 2016

Cash

36.4 m29.9 m17.3 m

Accounts Receivable

2.7 m2.4 m2.8 m

Inventories

686 k766 k5.5 m

Current Assets

40.3 m34.4 m26.7 m

PP&E

2 m2.4 m2.9 m

Goodwill

12 m12 m13.8 m

Total Assets

61.1 m55.6 m76.7 m

Accounts Payable

1.1 m1.6 m3.1 m

Total Debt

15.8 m23.9 m

Current Liabilities

11.1 m10.2 m40.8 m

Total Liabilities

57 m

Additional Paid-in Capital

200.7 m202.6 m235.7 m

Retained Earnings

(159.4 m)(173.1 m)(212.6 m)

Total Equity

41.3 m29.5 m19.8 m

Debt to Equity Ratio

0.5 x1.2 x

Debt to Assets Ratio

0.3 x0.3 x

Financial Leverage

1.5 x1.9 x3.9 x
USDQ2, 2016Q3, 2016Q1, 2017

Cash

17.1 m22.3 m12.2 m

Accounts Receivable

4.9 m4.6 m3.4 m

Inventories

8.7 m7.4 m6 m

Current Assets

32.5 m35.1 m23.1 m

PP&E

3.4 m3.3 m2.8 m

Goodwill

28.1 m28 m12 m

Total Assets

100.5 m102.1 m80.3 m

Accounts Payable

3.3 m3.5 m3.5 m

Current Liabilities

38.2 m39.6 m53 m

Additional Paid-in Capital

226.6 m235.1 m236.1 m

Retained Earnings

(193.3 m)(197.1 m)(218.1 m)

Total Equity

32.5 m36.8 m14.9 m

Financial Leverage

3.1 x2.8 x5.4 x
USDFY, 2014FY, 2015FY, 2016

Net Income

781 k(13.7 m)(39.8 m)

Depreciation and Amortization

512 k796 k2.9 m

Accounts Receivable

(417 k)320 k1 m

Inventories

(168 k)(80 k)492 k

Accounts Payable

510 k489 k(620 k)

Cash From Operating Activities

31.3 m(9.8 m)(16.5 m)

Purchases of PP&E

(733 k)(1.2 m)(549 k)

Cash From Investing Activities

(1.3 m)(1.2 m)(21.1 m)

Cash From Financing Activities

36 m4.4 m24.9 m

Interest Paid

1.2 m1.4 m867 k
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(3.2 m)(3.5 m)(9.8 m)(10.5 m)(3.8 m)(5.6 m)

Accounts Receivable

1.8 m1.7 m2.2 m2.5 m4.9 m4.6 m3.4 m

Inventories

775 k731 k814 k595 k8.7 m7.4 m6 m

Accounts Payable

1.4 m1.2 m1.9 m2.5 m3.3 m3.5 m3.5 m
USDY, 2017

Revenue/Employee

210.6 k

Financial Leverage

5.4 x

CareDx Market Value History

Traffic Overview of CareDx

CareDx Online and Social Media Presence

CareDx Company Life and Culture

You may also be interested in